AcelRX met primary endpoint in Phase 3 trial AcelRx Pharmaceuticals announced it had met the primary endpoint in the Phase 3 non-inferiority study of the sublingual Sufentanil NanoTab PCA System vs. IV PCA with morphine. The top-line data is expected to be released prior to market opening on November 15. AcelRx management will host an conference call at 8:00 a.m. EST to discuss the Phase 3 top-line results.
News For ACRX From The Last 14 Days
Check below for free stories on ACRX the last two weeks.
Subscribe for More Information
